Officials Visit Shenzhen True Flavor Biotech for Industry Research

Aug.08.2022
Officials Visit Shenzhen True Flavor Biotech for Industry Research
Shenzhen officials visit Shenzhen Zhenwei Bioscience to discuss their development plans and commend their innovative progress.

On August 4th, a delegation led by Cai Ying, Secretary of the Guangming District Committee in Shenzhen, including Shen Huaxin and Zhang Feng, both members of the District Committee, visited Shenzhen Truly Bio-Tech Co., Ltd. They were accompanied by Peng Hua, Deputy Director of the District Committee and Government Office, Lin Shuping, Director of the District Industrial and Information Bureau, Liu Kun, Secretary of the Yutang Street Party Working Committee, Liu Li, Deputy Director of the District Investment Promotion Service Center, and Zeng Peisheng, Deputy Director of the Guangming District Tobacco Monopoly Bureau. The general manager of Truly Bio-Tech, Zou Yang, and other members of management welcomed and hosted the delegation.


A research team conducted a site visit to the offices of Truly Flavored Biotech and received a detailed explanation from the company's leader on various aspects of the company's functional centers, including the introduction of top research equipment, the standardization of process systems, the improvement of talent, and the upgrading of industry intelligence. The team also observed the operation of the Aerosol Technology Research Institute, the pharmaceutical-grade GMP cleanroom, the quality control center, and the fragrance development center, gaining a thorough understanding of the current state of technology personnel, hardware and software facilities, and product development progress. The team engaged in in-depth discussions with staff members and gained a comprehensive understanding of the processes involved in raw material selection, quality testing, and new product research and development. The team fully recognized Truly Flavored Biotech's efforts to "promote innovation-led industry and drive development with scientific research" as a benchmark, a growth booster, and a long-term strategy.


After the visit, a symposium was held under the chairmanship of the Huanxin Executive Committee of the research group.


During the symposium, Secretary Cai Ying fully recognized the work of Zhenwei Biology. She pointed out that as a leading company in the electronic atomized liquid industry, Zhenwei Biology not only has a strong development momentum, but also actively undertakes corporate social responsibility. The company is also forward-thinking in research and innovation, market judgment, and new enterprise layout. At the same time, Secretary Cai Ying expressed deep concern for the company's future development plan. She hopes that Zhenwei Biology will further improve its industrial layout, seize opportunities for further development and expansion, and integrate into the overall development of the Guangming Science City. Meanwhile, the government and various departments of Guangming District will continue to implement pro-enterprise and supportive policies, providing top-notch services and quality space for long-term development and stability of enterprises. The government aims to maintain the vitality of the market, job security, and the welfare of the people in promoting the steady and progressive development of the local economy.


During the meeting, the research team listened to a report from Mr. Zou Yang, the General Manager of Zhenwei Biotech, on the progress and achievements of the company's phase work and the strategic planning for future development. Mr. Zou focused on the current national policies for the electronic atomized liquid industry, Zhenwei's development of new products in compliance with national standards, and the company's economic growth in the first half of the year. He stated that with the help of preferential policies from the government and various departments in Guangming District, Zhenwei Biotech's economic growth has been rapidly increasing since the first half of 2022. Furthermore, in order to better implement industry policy requirements, Zhenwei Biotech established the Zhenwei Biotech (Yunnan) Research Institute immediately after obtaining the tobacco monopoly production license, and is fully engaged in the research of tobacco-flavored atomized products. Zhenwei Biotech hopes to cooperate with the industry's upstream and downstream industries to create electronic atomized products with international influence.


The General Manager, Zou Yang, also stated that Zhenwei Biology will establish itself in Guangming, adhere to the real economy, persist in innovation, elevate its standards, strive to improve the company's efficiency and size, and firmly uphold the industry mission of "being a role model, setting an example, and leading the way." With a foundation in the electronic atomization liquid industry, they will develop in multiple modes, channels, and diversify cooperation, continuously improve market confidence with new development and achievements, make greater contributions to socio-economic development, and also hope that Zhenwei Biology will rely on its strong scientific research capabilities to make a positive contribution to the economic development of Guangming district.


The visit by district leaders is a strong recognition of the achievements in our company's development. In the future, Zhenwei Biological will proactively embrace regulation, adhere to industry policy requirements and government calls, increase research and development investment, and persist in pursuing high-quality development. We will contribute to the economic development of Guangming District and create a win-win outcome.


This article contains excerpts or reprints from third-party sources whose copyrights belong to the original media and authors. If there is any infringement, please contact us for deletion. Any individual or organization that wants to reprint this content should contact the author and refrain from direct reposting.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Malaysia Nicotine Vape Market Faces Legal Uncertainty Over Tax and Poisons List Ruling
Malaysia Nicotine Vape Market Faces Legal Uncertainty Over Tax and Poisons List Ruling
Malaysia’s Finance Minister Anwar Ibrahim said duties and taxes on nicotine-containing vape products will be determined in line with the Court of Appeal’s ruling on whether liquid or gel nicotine can be exempted from the Poisons List under the Poisons Act 1952, a case that could affect the legal basis for vape taxation, retail sales and future ban policy.
Jun.29
Philippine Customs Seizes $2.22 Million in Misdeclared Vape Products From China
Philippine Customs Seizes $2.22 Million in Misdeclared Vape Products From China
The Philippine Bureau of Customs said it intercepted nine containers of misdeclared vape and vape-related products from China at the Manila International Container Port, with an estimated value of about ₱137 millionor, about $2.22 million.
Jul.10
PMI to Launch IQOS in Argentina by End-2026 After Regulatory Shift, Targeting About 7 Million Smokers
PMI to Launch IQOS in Argentina by End-2026 After Regulatory Shift, Targeting About 7 Million Smokers
Philip Morris International (PMI) has confirmed plans to bring its IQOS heated tobacco device to Argentina by the end of 2026, after the Argentine government lifted long-standing restrictions and created a regulatory framework for heated tobacco, e-cigarettes and nicotine pouches.
News
Jun.26 by 2Firsts Perspectives
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
BAT New Categories Revenue Rises 18% in H1 2026 as Broad Portfolio Offers More Ways to Win—and Lose
British American Tobacco’s New Category revenue rose 18% at constant rates in the first half of 2026. Nicotine-pouch brand Velo expanded rapidly, while Vuse recovered as U.S. enforcement against illicit e-vapor products strengthened. Heated-tobacco platform glo remained under pressure, and cigarettes continued to provide most of the group’s profit and cash. Compared with PMI and JT, BAT has more routes to growth—but also greater regulatory, investment and execution risks across its broader portfolio.
BAT
Jul.30
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
U.S. technology and investigative publication WIRED has examined how nicotine analogs are emerging as a new challenge for the country’s vape regulatory framework. The article argues that after the U.S. expanded federal oversight of nicotine products in 2022, some manufacturers began using nicotine-like compounds such as 6-methyl-nicotine that may fall outside existing definitions. Researchers cited by WIRED said some nicotine analogs could be more potent than traditional nicotine, although human health impacts remain unclear. U.S. policymakers are considering broader definitions of nicotine to bring these compounds under federal oversight.
Jul.27
Virginia Tightens Vape and Tobacco Retail Enforcement, With Fines Up to $15,000 Per Unlisted Product
Virginia Tightens Vape and Tobacco Retail Enforcement, With Fines Up to $15,000 Per Unlisted Product
A new Virginia law that took effect on July 1, 2026, requires retailers to obtain permits to sell liquid nicotine, vape and tobacco products, while directing Virginia ABC to conduct inspections and verify that stores sell only products listed in the state directory.
Jul.20